CMIから、DANCE Trial Published
重度の蜂巣炎患者の12日間に対する6日間の抗生物質治療：多施設無作為化、二重盲検、プラセボ対照、非劣性試験。
https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(19)30504-X/fulltext
感想 まとめ
非劣勢でした。治療期間ショートの流れは止まらない。
しかし、この流れに乗るにはCRPやWBCを確認するだけでなく、全身状態の評価能力向上も必要だと思う。
- non-inferiority trial
- P : severe cellulitis who were treated with intravenous flucloxacillin.
- E : additional 6 days of oral flucloxacillin
- C : additional 6 days of placebo
- O : The primary outcome was cure by day 14, without relapse by day 28.
- cured in the 12- and 6-day groups (ARR 0.7 percentage points, 95% CI: -15.0 to 16.3)
Abstract
Objectives
To investigate whether 6 days of antibiotic treatment duration is non-inferior to 12 days in patients hospitalised for cellulitis.
Methods
This multicentre, randomised, double-blind, placebo-controlled, non-inferiority trial enrolled adult patients hospitalised for severe cellulitis who were treated with intravenous flucloxacillin. At day 6 participants with symptom improvement who were afebrile were randomised between an additional 6 days of oral flucloxacillin or placebo in a 1:1 ratio, stratified for diabetes and hospital. The primary outcome was cure by day 14, without relapse by day 28. Secondary outcomes included a modified cure assessment and relapse rate by day 90.
Results
Between August 2014 and June 2017, 151 of 248 included participants were randomised. The intention-to-treat population consisted of 76 and 73 participants allocated to 12 and 6 days antibiotic therapy, respectively (mean age 62 years, 67% males, 24% diabetics). 38/76 (50.0%) and 36/73 (49.3%) were cured in the 12- and 6-day groups (ARR 0.7 percentage points, 95% CI: -15.0 to 16.3). Cure rates were 56/76 (73.7%) and 49/73 (67.1%) with the modified cure assessment (ARR 6.6, 95% CI: -8.0 to 20.8). After initial cure without relapse, day 90 relapse rates were higher in the 6-day group (6% vs 24%, p<0.05).
Conclusions
Given the wide confidence intervals, we can neither confirm nor refute our hypothesis that 6 days of therapy is non-inferior to 12 days of therapy. However, a 6-day course resulted in significantly more frequent relapses by day 90. These findings require confirmation in future studies.
